Guardant Health Inc (GH) - Product Pipeline Analysis, 2024 Update

Summary


Guardant Health Inc (Guardant Health) is a precision oncology company that commercializes novel therapeutics for cancer. The company develops proprietary digital sequencing technology used to detect individual genomic alterations. It offers Guardant360, a tool for early cancer detection used during cancer treatment for residual disease monitoring and also recurrence monitoring. The company test platform includes GuardantOMNI, GuardantINFINITY and GuardantINFORM. Guardant Health also develops a cloud-based information platform for liquid biopsy-based genomic testing in cancer treatments. The company has operations in the Netherlands, Japan, Singapore, and the US. Guardant Health is headquartered in Pao Alto, California, the US.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:
  • The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
  • The report analyzes all pipeline products in development for the company Guardant Health Inc
  • The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
  • The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
  • The report provides detailed description of products in development, technical specification and functions
  • The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
  • Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
  • Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
  • To formulate effective Research & Development strategies
  • Develop market-entry and market expansion strategies
  • Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
  • Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note:Some sections may be missing if data is unavailable for the company


Guardant Health Inc Company Overview
Guardant Health Inc Company Snapshot
Guardant Health Inc Pipeline Products and Ongoing Clinical Trials Overview
Guardant Health Inc – Pipeline Analysis Overview
Guardant Health Inc - Key Facts
Guardant Health Inc - Major Products and Services
Guardant Health Inc Pipeline Products by Development Stage
Guardant Health Inc Ongoing Clinical Trials by Trial Status
Guardant Health Inc Pipeline Products Overview
Anti-RSP03 Antibody Based Blood Test
Anti-RSP03 Antibody Based Blood Test Product Overview
cfDNA Diagnostic Assay
cfDNA Diagnostic Assay Product Overview
Gene-Based Test - Lung Cancer
Gene-Based Test - Lung Cancer Product Overview
Gene-Based Test - Lung Cancer Clinical Trial
Guardant Reveal Blood Test - Multiple Cancers
Guardant Reveal Blood Test - Multiple Cancers Product Overview
Guardant Reveal Blood Test - Multiple Cancers Clinical Trial
Guardant Shield IVD-CRC Test
Guardant Shield IVD-CRC Test Product Overview
Guardant Shield IVD-CRC Test Clinical Trial
Guardant Shield Lung Test
Guardant Shield Lung Test Product Overview
Guardant Shield Lung Test Clinical Trial
Guardant360 CDx Test - Camizestrant
Guardant360 CDx Test - Camizestrant Product Overview
Guardant360 CDx Test - Pembrolizumab
Guardant360 CDx Test - Pembrolizumab Product Overview
Guardant360 CDx Test - Taletrectinib
Guardant360 CDx Test - Taletrectinib Product Overview
Guardant360 CDx Test - Tepotinib
Guardant360 CDx Test - Tepotinib Product Overview
Guardant360 Companion Diagnostic Assay - Glesatinib
Guardant360 Companion Diagnostic Assay - Glesatinib Product Overview
Guardant360 Liquid Biopsy Test
Guardant360 Liquid Biopsy Test Product Overview
Guardant360 TissueNext - Expanded Version
Guardant360 TissueNext - Expanded Version Product Overview
Guardant360 TissueNext PD-L1 Test
Product Status
GuardantOMNI Test - Imfinzi
GuardantOMNI Test - Imfinzi Product Overview
LUNAR-2 Assay
LUNAR-2 Assay Product Overview
LUNAR-2 Assay Clinical Trial
Next-Generation CGP Tissue Assay
Next-Generation CGP Tissue Assay Product Overview
Shield CRC + Lung
Shield CRC + Lung Product Overview
Shield Multi-Cancer
Shield Multi-Cancer Product Overview
Smart Liquid Biopsy
Smart Liquid Biopsy Product Overview
Guardant Health Inc - Key Competitors
Guardant Health Inc - Key Employees
Guardant Health Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Guardant Health Inc, Recent Developments
Jun 04, 2024: Guardant Health Introduces New Guardant360 Tissuenext Test With Nearly 500 Biomarkers To Identify More Treatment Options For Patients With Advanced Cancer
Jun 03, 2024: Guardant Health and Washington University to Present Study at 2024 Asco Meeting Highlighting Utility of ctDNA to Address Racial Inequities in the Use of Targeted Therapies and Enrollment in Clinical Trials
May 30, 2024: Guardant Health to Present Studies at 2024 ASCO Annual Meeting Highlighting Contributions of Its Blood Tests and Real-World Data to Advancing Precision Oncology and Cancer Screening
May 24, 2024: Guardant wins FDA AdCom backing for colon cancer test
May 22, 2024: Guardant Health to Participate in Upcoming Investor Conferences
May 21, 2024: Guardant’s tumour mutation profiling test gains EU IVDR certification
May 16, 2024: Guardant Health to present real-world data supporting performance of Shield blood test for colorectal cancer screening at 2024 Digestive Disease Week
May 07, 2024: Guardant Health Surpasses 500 Peer-reviewed Publications Milestone
Apr 22, 2024: FDA Advisory Panel Review of Guardant Health’s Shield Blood Test to Screen for Colorectal Cancer to Be Held on May 23
Apr 03, 2024: Guardant Health to Present Data Highlighting Application of Epigenomics to Advance Precision Oncology at 2024 AACR Annual Meeting
Appendix
Methodology
About GlobalData
Contact Us
Disclaimer
List of Tables
Guardant Health Inc Pipeline Products and Ongoing Clinical Trials Overview
Guardant Health Inc Pipeline Products by Equipment Type
Guardant Health Inc Pipeline Products by Indication
Guardant Health Inc Ongoing Clinical Trials by Trial Status
Guardant Health Inc, Key Facts
Guardant Health Inc, Major Products and Services
Guardant Health Inc Number of Pipeline Products by Development Stage
Guardant Health Inc Pipeline Products Summary by Development Stage
Guardant Health Inc Ongoing Clinical Trials by Trial Status
Guardant Health Inc Ongoing Clinical Trials Summary
Anti-RSP03 Antibody Based Blood Test - Product Status
Anti-RSP03 Antibody Based Blood Test - Product Description
cfDNA Diagnostic Assay - Product Status
cfDNA Diagnostic Assay - Product Description
Gene-Based Test - Lung Cancer - Product Status
Gene-Based Test - Lung Cancer - Product Description
Gene-Based Test - Lung Cancer - Prospective Feasibility Study of Cell Free Circulating Tumor DNA for the Diagnosis and Treatment Monitoring in Early-stage Non-small Cell Lung Cancer
Guardant Reveal Blood Test - Multiple Cancers - Product Status
Guardant Reveal Blood Test - Multiple Cancers - Product Description
Guardant Reveal Blood Test - Multiple Cancers - ORACLE: Observation of ResiduAl Cancer with Liquid Biopsy Evaluation
Guardant Shield IVD-CRC Test - Product Status
Guardant Shield IVD-CRC Test - Product Description
Guardant Shield IVD-CRC Test - Blood-Based Colorectal Cancer (CRC) Screening Implementation Into Clinical Practice in the Outpatient Clinical Settings in the Appalachian Highlands
Guardant Shield IVD-CRC Test - The Ohio State University Guardant Shield Colorectal Cancer Screening Project
Guardant Shield IVD-CRC Test - Understanding Patient Preference on Colorectal Cancer Screening Options
Guardant Shield IVD-CRC Test - Understanding Patient Preference on Colorectal Cancer Screening Options
Guardant Shield Lung Test - Product Status
Guardant Shield Lung Test - Product Description
Guardant Shield Lung Test - Screening for High Frequency Malignant Disease
Guardant360 CDx Test - Camizestrant - Product Status
Guardant360 CDx Test - Camizestrant - Product Description
Guardant360 CDx Test - Pembrolizumab - Product Status
Guardant360 CDx Test - Pembrolizumab - Product Description
Guardant360 CDx Test - Taletrectinib - Product Status
Guardant360 CDx Test - Taletrectinib - Product Description
Guardant360 CDx Test - Tepotinib - Product Status
Guardant360 CDx Test - Tepotinib - Product Description
Guardant360 Companion Diagnostic Assay - Glesatinib - Product Status
Guardant360 Companion Diagnostic Assay - Glesatinib - Product Description
Guardant360 Liquid Biopsy Test - Product Status
Guardant360 Liquid Biopsy Test - Product Description
Guardant360 TissueNext - Expanded Version - Product Status
Guardant360 TissueNext - Expanded Version - Product Description
Product Status
Guardant360 TissueNext PD-L1 Test - Product Description
GuardantOMNI Test - Imfinzi - Product Status
GuardantOMNI Test - Imfinzi - Product Description
LUNAR-2 Assay - Product Status
LUNAR-2 Assay - Product Description
LUNAR-2 Assay - Evaluation of the ctDNA LUNAR Test in an Average Patient Screening Episode
Next-Generation CGP Tissue Assay - Product Status
Next-Generation CGP Tissue Assay - Product Description
Shield CRC + Lung - Product Status
Shield CRC + Lung - Product Description
Shield Multi-Cancer - Product Status
Shield Multi-Cancer - Product Description
Smart Liquid Biopsy - Product Status
Smart Liquid Biopsy - Product Description
Guardant Health Inc, Key Employees
Guardant Health Inc, Subsidiaries
Glossary
List of Figures
Guardant Health Inc Pipeline Products by Equipment Type
Guardant Health Inc Pipeline Products by Development Stage
Guardant Health Inc Ongoing Clinical Trials by Trial Status

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings